- Published on
Pathology-Parkinson's Disease
I. Definition & Epidemiology:
I. Definition & Epidemiology:
- Definition: Parkinson's disease is a neurodegenerative disorder. Clinically, it's characterized by parkinsonism (a group of motor symptoms); histologically (microscopically), it's defined by neuronal loss in the brain and the presence of Lewy bodies (abnormal protein aggregates) concentrated in the substantia nigra. Crucially, parkinsonism itself is not diagnostic of Parkinson's Disease.
- Epidemiology: Primarily affects the elderly. Prevalence is approximately 1% in individuals over 60 years old.
- Mostly Unknown: The cause of most Parkinson's cases remains unclear.
- Genetic Factors (Rare Cases): Rarely, inherited mutations in the PARK1 gene (chromosome 4), which codes for α-synuclein (a protein component of Lewy bodies), are implicated.
- Dopamine Deficiency: Neurons in the substantia nigra project to the putamen and globus pallidus (basal ganglia structures crucial for movement). These neurons release dopamine, a neurotransmitter essential for controlling movement. In Parkinson's, dopamine release is significantly reduced.
- Movement Disorder: The lack of dopamine leads to the characteristic movement disorders.
- Parkinsonism: The classic triad of symptoms includes:
- Tremor: Involuntary shaking.
- Rigidity: Stiffness and resistance to movement.
- Bradykinesia: Slowness of movement.
- Important Note: Parkinsonism can result from various causes (drugs, toxins, infections, trauma) and isn't solely indicative of Parkinson's disease.
- Macroscopy (Gross Examination): Shows pallor (loss of color) in the substantia nigra and locus ceruleus (brain regions).
- Histopathology (Microscopic Examination): Reveals:
- Loss of pigmented neurons in the substantia nigra.
- Presence of Lewy bodies within remaining neurons.
- Treatment: Dopamine-replacement therapies can alleviate parkinsonism symptoms. However, these treatments do not slow or stop the disease's progression.
- Variable Progression: The rate of disease progression varies significantly between individuals.
- Published on
Pathology-Motor Neurone Disease (MND)
I. Definition & Epidemiology:
I. Definition & Epidemiology:
- Definition: MND is a group of neurodegenerative diseases causing selective loss of motor neurons. This means the nerve cells that control voluntary muscle movement are progressively destroyed.
- Epidemiology:
- Rare disease: Annual incidence 1-5 per 100,000.
- Slight male predominance.
- Typical onset: 50-70 years old.
- Mostly Idiopathic: In most cases (90%), the cause is unknown.
- Familial (Inherited): Approximately 10% of cases are inherited, showing a genetic component.
- Genetic Links: Several genes associated with familial MND have been identified, including SOD1, TDP-43, and FUS.
- Poorly Understood: The precise mechanisms driving MND remain largely unclear, even with insights from familial cases.
- RNA Metabolism Dysfunction: A leading hypothesis points to defects in RNA metabolism as a crucial factor in motor neuron degeneration. This is based on the properties of TDP-43 and FUS proteins.
- TDP-43 & FUS: Both are RNA/DNA-binding proteins with similar structures. Their dysfunction is strongly implicated in MND development.
- Muscular Symptoms: Asymmetrical muscle weakness and wasting (atrophy), muscle twitching (fasciculations), and muscle stiffness (spasticity) in limbs are common early signs.
- Bulbar Symptoms: Difficulty with swallowing (dysphagia), chewing, speaking (dysarthria), coughing, and breathing (dyspnea) are characteristic as the disease progresses and affects the muscles controlling these functions.
- Cognitive Changes: Cognitive impairment can also occur in some cases.
- Macroscopy (Gross Examination): The anterior roots of the spinal cord (which carry motor neuron axons) are atrophied (shrunken).
- Histopathology (Microscopic Examination):
- Selective loss of motor neurons in the motor cortex (brain) and anterior horns of the spinal cord is the defining feature.
- In sporadic (non-inherited) MND, remaining motor neurons often contain abnormal protein inclusions that include ubiquitin and TDP-43.
- Progressive & Fatal: MND is typically progressive, leading to death within a few years.
- Cause of Death: Aspiration pneumonia (lung infection from inhaling food or saliva due to swallowing difficulties) is a frequent cause of death.
- Published on
Pathology- Huntington's Disease
I. Definition & Epidemiology:
I. Definition & Epidemiology:
- Definition: HD is an inherited, neurodegenerative disorder resulting from a mutation in the HTT gene. This mutation leads to the production of a dysfunctional huntingtin protein.
- Epidemiology:
- Prevalence: 5-10 per 100,000 globally, with geographical variation.
- Onset: Typically 35-45 years, but can occur at any age.
- Sex: Affects men and women equally.
- Inheritance: Autosomal dominant (only one affected copy of the gene is needed to develop the disease).
- HTT Gene: Contains a CAG trinucleotide repeat sequence.
- Normal HTT: Less than 36 CAG repeats.
- Mutant HTT: More than 36 CAG repeats. The number of repeats directly correlates with disease severity and age of onset (more repeats = earlier onset, greater severity).
- Anticipation: The number of CAG repeats tends to increase in subsequent generations, leading to earlier onset and more severe disease in offspring. This phenomenon is known as anticipation.
- Huntingtin Protein (HTT): The protein encoded by the HTT gene has various cellular functions and is expressed throughout the body, but is most concentrated in the brain and testes.
- Mechanism of Disease: Mutated huntingtin protein is cytotoxic (toxic to cells), particularly affecting neurons in the caudate nucleus and putamen (basal ganglia structures crucial for movement control).
- Early Symptoms: Uncontrolled, jerky, involuntary movements (chorea).
- Progressive Disease: Over time, HD leads to progressive motor, neuropsychiatric (mood disorders, cognitive issues), and cognitive decline, ultimately culminating in dementia.
- Macroscopy: Significant atrophy (shrinking) of the caudate nucleus and putamen. Cortical atrophy may also be present.
- Histopathology: Marked neuronal loss in the caudate nucleus. Surviving neurons contain excessive amounts of the mutated huntingtin protein.
- Survival: Average survival is approximately 20 years from symptom onset, but varies depending on the number of CAG repeats (more repeats = shorter survival).
- Cause of Death: Often pneumonia or cardiac failure due to mutated huntingtin expression in cardiac muscle.
- Published on
Pathology- Myasthenia Gravis
I. Definition:
I. Definition:
- Myasthenia gravis (MG) is an autoimmune disease. This means the body's own immune system mistakenly attacks healthy tissues.
- Specifically, autoantibodies (self-attacking antibodies) target the nicotinic acetylcholine receptor (nAChR) at the neuromuscular junction. This is the point where nerves meet muscles.
- Rare: Annual incidence is low (20 per 100,000).
- Age and Gender: More common in women under 50 and men over 50. Note the age difference between genders.
- Unknown Trigger: The precise cause of autoantibody production is unclear. This is a crucial point to remember – we don't fully understand why the immune system attacks the nAChR.
- Thymus Involvement: A significant link exists between MG and the thymus gland (located in the chest). Up to 75% of patients have thymus abnormalities:
- Thymoma: A tumor of the thymus.
- Hyperplasia: Enlargement of the thymus.
- Thymus as a Source?: It's hypothesized that the abnormal thymus may be the site where these autoantibodies are produced.
- Neuromuscular Junction: Recall that the nAChR is crucial for muscle contraction. Acetylcholine, a neurotransmitter, binds to it, triggering muscle activation.
- Autoantibody Interference: The autoantibodies bind to the nAChR, preventing acetylcholine from binding effectively. This reduces the muscle's ability to contract.
- Result: Impaired muscle contraction and weakness.
- Key Symptom: Muscle Fatigue: Weakness that worsens with activity and improves with rest is the hallmark of MG. This is a fundamental characteristic.
- Muscle Groups Affected (in order of typical involvement):
- Extraocular muscles (eye muscles) – leading to diplopia (double vision) and ptosis (drooping eyelids).
- Bulbar muscles (muscles controlling swallowing and speech) – difficulty swallowing (dysphagia) and speech impairment (dysarthria).
- Facial muscles
- Neck muscles
- Limb girdle muscles (shoulders and hips)
- Trunk muscles
- Diagnostic Challenge: Symptoms can be subtle and easily mistaken for other conditions, making diagnosis difficult. This highlights the importance of considering MG in patients with unexplained muscle weakness.
- Generally Favorable: Most patients respond well to treatment. The disease is typically relapsing (symptoms come and go) but not progressive (does not steadily worsen over time).
- Thymoma Exception: Patients with aggressive thymoma may have a poorer prognosis due to the cancerous nature of the tumor.
- Autoimmune nature: MG is caused by the body attacking its own nAChRs.
- Neuromuscular junction dysfunction: The problem lies in the communication between nerves and muscles.
- Muscle fatigue: The defining symptom.
- Thymus gland involvement: A significant association exists between MG and thymic abnormalities.
- Variable presentation: Diagnosis can be challenging due to subtle or atypical symptoms.
- Published on
Pathology-Guillain-Barré Syndrome (GBS)
I. Definition & Epidemiology:
I. Definition & Epidemiology:
- Definition: Guillain-Barré syndrome (GBS) is an acute demyelinating polyneuropathy. This means it's a rapid onset disorder affecting many nerves, characterized by damage to the myelin sheath (the protective covering around nerves). It typically appears 1-2 weeks after a respiratory or gastrointestinal infection.
- Rarity: GBS is a rare disease with an annual incidence of only 1-2 cases per 100,000 people.
- Infectious Triggers: The most common triggers are infections caused by:
- Campylobacter jejuni
- Mycoplasma
- Cytomegalovirus (CMV)
- HIV
- Varicella-zoster virus (VZV)
- Epstein-Barr virus (EBV)
- Other Associations: GBS can also be associated with:
- Vaccination (although this is rare and the benefits of vaccination far outweigh the risk)
- Surgery
- Malignancy (cancer)
- Idiopathic Cases: In a significant number of cases, no clear cause can be identified.
- Cross-Reactivity: The leading theory suggests that the immune system, while fighting off an infection, mistakenly attacks the myelin sheath of peripheral nerves. This happens because an antigen (a protein on the surface of the pathogen) is similar to an antigen on the nerve myelin, leading to an immune "cross-reaction".
- Demyelination & Polyneuropathy: This attack on the myelin causes demyelination (loss of the myelin sheath), resulting in an acute polyneuropathy (a condition affecting many peripheral nerves).
- Initial Symptoms: GBS typically begins with sudden onset of tingling and numbness in the fingers and toes (distal paresthesia).
- Progressive Weakness: Over several weeks, the muscle weakness spreads proximally (from the extremities towards the trunk and center of the body), a hallmark characteristic of GBS.
- Major Risk: Progressive ventilatory failure (difficulty breathing) is the most serious complication and a leading cause of death. This necessitates close monitoring and potential respiratory support.
- Recovery Rate: Approximately 85% of patients make a complete or near-complete recovery.
- Long-Term Disability: About 10% of patients are unable to walk without assistance one year after diagnosis.
- Acute vs. Chronic: GBS is acute, meaning it develops rapidly. Contrast this with chronic conditions which develop slowly over time.
- Polyneuropathy: Understand that "poly" means many and "neuropathy" refers to nerve dysfunction. Therefore, polyneuropathy means widespread nerve dysfunction.
- Demyelination: Focus on the concept of immune system cross-reactivity leading to damage of the myelin sheath and subsequent nerve dysfunction.
- Ascending Weakness: The progressive spread of weakness from the periphery (fingers and toes) to the center of the body is a critical diagnostic feature.
- Ventilatory Failure: Recognize this as the most significant threat to life in GBS patients.
- Published on
Pathology- Creutzfeldt-Jakob Disease (CJD)
I. Definition & Epidemiology:
I. Definition & Epidemiology:
- Definition: CJD is a rare, fatal spongiform encephalopathy caused by the accumulation of misfolded prion protein (PrP) resistant to normal cellular breakdown. It's the most common human prion disease.
- Epidemiology: Extremely rare, with an annual incidence of approximately 1 per 1,000,000.
- Sporadic CJD: Spontaneous, random misfolding of normal PrP into the abnormal PrP form. The exact mechanism remains unclear.
- Familial CJD: Inherited mutations in the PRNP gene increase the likelihood of PrP misfolding.
- Variant CJD (vCJD): Believed to be transmitted via consumption of beef contaminated with PrPSc from cattle with bovine spongiform encephalopathy (BSE, "mad cow disease").
- Misfolded Protein Propagation: The presence of abnormal PrPSc acts as a template, causing normal PrPC to misfold into the abnormal form.
- Exponential Growth & Cell Death: This process leads to an exponential increase in PrPSc, ultimately causing neuronal cell death and the characteristic brain damage.
- Sporadic CJD: Typically affects middle-aged and elderly individuals. Onset is marked by rapidly progressing neurological symptoms.
- Variant CJD (vCJD): Affects younger individuals (<30 years old). initially presents with psychiatric symptoms, followed by cerebellar ataxia (problems coordination and balance) dementia. < />pan>Key difference from sporadic CJD.
- Sporadic CJD & vCJD: Both show spongiform changes (vacuolation of grey matter), neuronal loss (death of nerve cells), and gliosis (scarring in the brain).
- Variant CJD (vCJD only): The presence of numerous "florid plaques" composed of amyloid forms of PrPSc is a key distinguishing neuropathological feature. These are absent in other CJD forms.
- Currently, no effective treatment exists for CJD. The disease is invariably fatal.
- Published on
- Published on
Pathology- Vasculitis
Definition: Vasculitis encompasses a group of diseases where inflammation and damage to blood vessels are the primary pathology. This damage can affect vessels of varying sizes, leading to diverse clinical presentations.
Types of Vasculitis:
This guide outlines key features to differentiate between the vasculitides discussed. Remember that overlap exists, and accurate diagnosis often requires biopsy and serological testing (ANCA).
1. Giant Cell (Cranial or Temporal) Arteritis:
Definition: Vasculitis encompasses a group of diseases where inflammation and damage to blood vessels are the primary pathology. This damage can affect vessels of varying sizes, leading to diverse clinical presentations.
Types of Vasculitis:
This guide outlines key features to differentiate between the vasculitides discussed. Remember that overlap exists, and accurate diagnosis often requires biopsy and serological testing (ANCA).
1. Giant Cell (Cranial or Temporal) Arteritis:
- Vessel Size: Medium and large arteries.
- Location: Primarily head and neck arteries (temporal artery most commonly).
- Demographics: Adults >50 years old.
- Presentation: Weeks to months of fever, anorexia, weight loss, headache, scalp tenderness, jaw claudication (pain with chewing).
- Serious Complications: Ocular involvement (blindness), aortic aneurysm (25% of cases).
- Diagnosis: Temporal artery biopsy (positive in only 60% due to focal nature of inflammation); shows lymphohistiocytic infiltrate, media disruption, and often giant cell reaction.
- Vessel Size: Medium-sized arteries.
- Presentation: Systemic vasculitis leading to aneurysm formation and vessel narrowing. Relatively rare with strict diagnostic criteria.
- Organ Involvement: Gastrointestinal tract (abdominal pain), nervous system (peripheral nerve palsies), muscles (muscle aches).
- Diagnosis: Imaging showing vessel narrowing and aneurysms; biopsy confirming necrotizing vasculitis.
- Vessel Size: Small vessels.
- Presentation: Systemic vasculitis with prominent upper respiratory tract, lung, and kidney involvement. Characterized by c-ANCA positivity.
- Symptoms: Nasal symptoms, acute renal failure, pulmonary symptoms.
- Diagnosis:
- Renal biopsy: Focal segmental necrotizing glomerulonephritis with crescent formation (identical to microscopic polyangiitis).
- Lung biopsy: Large necrotizing granulomatous inflammation and necrotizing vasculitis.
- Treatment: Aggressive immunosuppression is crucial to prevent death.
- Vessel Size: Small vessels.
- Presentation: Systemic vasculitis with significant renal and lung involvement. Characterized by p-ANCA positivity.
- Demographics: Adults, median age 55.
- Symptoms: Acute renal failure, pulmonary symptoms.
- Diagnosis:
- Renal biopsy: Focal segmental necrotizing glomerulonephritis with crescent formation (identical to Wegener's granulomatosis).
- Lung biopsy: Marked alveolar hemorrhage and necrotizing capillaritis within alveolar septa.
- Treatment: Aggressive immunosuppression is essential for survival.
- Published on
- Published on
